No Data
No Data
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
Hong Kong stocks fluctuate | CRO concept continues to decline, domestic biomedical investment and financing still at the bottom, overseas business development uncertainty increases.
CRO concept stocks continue to decline. As of the time of writing, wuxi apptec (02359) is down 6.13%, trading at 45.9 Hong Kong dollars; tigermed (03347) is down 5.88%, trading at 32 Hong Kong dollars; pharmaron (03759) is down 5.71%, trading at 13.2 Hong Kong dollars.
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks